Skip to content

Study · Randomized controlled trial · 2025

4 results

Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study.

Dahl K, Toubro S, Dey S, Duque do Vale R, Flint A, Gasiorek A, Heydorn A, Jastreboff AM, Key C, Petersen SB, Vegge A, Adelborg K

Lancet (London, England)20 Jun 2025Cited by 59 (Europe PMC)

PMID40550231 (opens in a new tab)DOI10.1016/s0140-6736(25)01185-7 (opens in a new tab)PepBankPUB-40550231
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In participants with overweight or obesity, amycretin bodyweight change was -24·3% versus -1·1% with placebo at week 36.

    In plain wordsIn participants with overweight or obesity, amycretin reduced bodyweight more than placebo at week 36 in Part B.

    Peptide
    Amycretin
    Outcome
    DecreaseBodyweight change at week 36, Part B
    Study

    n: not reported in source

    Comparator
    placebo
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    60 mg once weekly · subcutaneous · 36 weeksAs given in this study (human).

    Measurements

    Bodyweight change from baseline
    −24.3%
    amycretin, Part B, 60 mg, week 36
    Bodyweight change from baseline
    −1.1%
    placebo, Part B, 60 mg, week 36

    Source sentences

    Summary
    Estimated mean bodyweight change from baseline was significantly (Parts A-D: p<0·0001; Part E: p=0·0003) higher with amycretin versus placebo in Part B (60 mg, -24·3% vs -1·1%; week 36)
    1 context sentence
    Summary · context
    In this randomised, placebo-controlled, phase 1b/2a study, we investigated the safety, tolerability, pharmacokinetics, and effects on bodyweight of subcutaneous injection of amycretin in participants aged 18-55 years with overweight or obesity (BMI 27·0-39·9 kg/m2).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In participants with overweight or obesity, amycretin bodyweight change was -22·0% versus 1·9% with placebo at week 36.

    In plain wordsIn participants with overweight or obesity, amycretin reduced bodyweight more than placebo at week 36 in Part C.

    Peptide
    Amycretin
    Outcome
    DecreaseBodyweight change at week 36, Part C
    Study

    n: not reported in source

    Comparator
    placebo
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    20 mg once weekly · subcutaneous · 36 weeksAs given in this study (human).

    Measurements

    Bodyweight change from baseline
    −22%
    amycretin, Part C, 20 mg, week 36
    Bodyweight change from baseline
    1.9%
    placebo, Part C, 20 mg, week 36

    Source sentences

    Summary
    Part C (20 mg, -22·0% vs 1·9%; week 36)
    1 context sentence
    Summary · context
    In this randomised, placebo-controlled, phase 1b/2a study, we investigated the safety, tolerability, pharmacokinetics, and effects on bodyweight of subcutaneous injection of amycretin in participants aged 18-55 years with overweight or obesity (BMI 27·0-39·9 kg/m2).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In participants with overweight or obesity, amycretin bodyweight change was -16·2% versus 2·3% with placebo at week 28.

    In plain wordsIn participants with overweight or obesity, amycretin reduced bodyweight more than placebo at week 28 in Part D.

    Peptide
    Amycretin
    Outcome
    DecreaseBodyweight change at week 28, Part D
    Study

    n: not reported in source

    Comparator
    placebo
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    5 mg once weekly · subcutaneous · 28 weeksAs given in this study (human).

    Measurements

    Bodyweight change from baseline
    −16.2%
    amycretin, Part D, 5 mg, week 28
    Bodyweight change from baseline
    2.3%
    placebo, Part D, 5 mg, week 28

    Source sentences

    Summary
    Part D (5 mg, -16·2% vs 2·3%; week 28)
    1 context sentence
    Summary · context
    In this randomised, placebo-controlled, phase 1b/2a study, we investigated the safety, tolerability, pharmacokinetics, and effects on bodyweight of subcutaneous injection of amycretin in participants aged 18-55 years with overweight or obesity (BMI 27·0-39·9 kg/m2).
  4. 04HumanRandomized controlled trialEfficacy outcome

    In participants with overweight or obesity, amycretin bodyweight change was -9·7% versus 2·0% with placebo at week 20.

    In plain wordsIn participants with overweight or obesity, amycretin reduced bodyweight more than placebo at week 20 in Part E.

    Peptide
    Amycretin
    Outcome
    DecreaseBodyweight change at week 20, Part E
    Study

    n: not reported in source

    Comparator
    placebo
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1·25 mg once weekly · subcutaneous · 20 weeksAs given in this study (human).

    Measurements

    Bodyweight change from baseline
    −9.7%
    amycretin, Part E, 1.25 mg, week 20
    Bodyweight change from baseline
    2%
    placebo, Part E, 1.25 mg, week 20

    Source sentences

    Summary
    and Part E (1·25 mg, -9·7% vs 2·0%; week 20).
    1 context sentence
    Summary · context
    In this randomised, placebo-controlled, phase 1b/2a study, we investigated the safety, tolerability, pharmacokinetics, and effects on bodyweight of subcutaneous injection of amycretin in participants aged 18-55 years with overweight or obesity (BMI 27·0-39·9 kg/m2).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2NCT06064006

A Research Study to See How a New Medicine (NNC0487-0111) Works in People With Overweight or Obesity When Injected Under the Skin

Novo Nordisk A/Sn = 12515 Sept 2023 to 27 Nov 2024

Obesity · Overweight

Trial pageClinicalTrials.govUpdated 19 Nov 2025

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.